Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in Germany

Key Points

Patients with HR+/HER2- early breast cancer frequently exhibit high-risk characteristics that negatively affect prognosis.
A significant proportion of HR+/HER2- patients present with adverse clinicopathological features, necessitating improved treatments.
Observational analysis illustrates the urgent need for new treatment strategies in managing this specific patient population.
Findings suggest that tailored interventions may be crucial to address the challenges faced by high-risk HR+/HER2- breast cancer patients.

Abstract

A considerable subset of patients with HR+/HER2- EBC present with high-risk clinicopathological characteristics, which indicate a negative impact on prognosis, thus highlighting the need for novel treatment strategies for this patient population.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Däßler et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75f3ac6e9836116a2a74d https://doi.org/https://doi.org/10.1016/j.ctarc.2026.101122

Bookmark

View Full Paper